Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells

Journal of Neuroscience

Volumn 34, Issue 44, 2014, Pages 14644-14651

  Lindberg, Nanna ^a,b,c   Jiang, Yiwen ^a   Xie, Yuan ^a   Bolouri, Hamid ^c   Kastemar, Marianne ^a   Olofsson, Tommie ^d   Holland, Eric C ^b,c,e   Uhrbom, Lene ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c USA   (United States)

^d The National board of Forensic Medicine   (Sweden)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Astrocytoma; Cell of origin; Glioma; Low grade glioma; Oligodendroglioma; PDGF

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLYCOPROTEIN GP 39; HERMES ANTIGEN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE B; TRANSCRIPTOME; VIMENTIN; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; EXPERIMENTAL NEOPLASM; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NEWBORN; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIAL TUMOR; ONCOGENE; ONCOGENE K RAS; PROTEIN EXPRESSION; REPLICATION COMPETENT AVIAN RETROVIRUS; RETROVIRUS; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BRAIN TUMOR; CELL LINEAGE; METABOLISM; NEURAL STEM CELL; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINEAGE; MICE; MICE, TRANSGENIC; NEURAL STEM CELLS; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PROTO-ONCOGENE PROTEINS P21(RAS); VIMENTIN;

EID: 84908317863     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2977-14.2014     Document Type: Article

References (37)

1. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK (1998) The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A 95: 14950–14955. CrossRef Medline
2. Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, Richardson WD, Raff MC (1992) Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70:31– 46. CrossRef Medline
3. Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D (2009) Adult supratentorial low-grade glioma: long-term experience at a single institution. Int J Radiat Oncol Biol Phys 75:1401–1407. CrossRef Medline
4. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, et al. (2013) The somatic genomic landscape of glioblastoma. Cell 155:462– 477. CrossRef Medline
5. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913–1925. CrossRef Medline
6. Hambardzumyan D, Cheng YK, Haeno H, Holland EC, Michor F (2011) The probable cell of origin of NF1and PDGF-driven glioblastomas. PLoS One 6:e24454. CrossRef Medline
7. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25:55–57. CrossRef Medline
8. Hu JG, Fu SL, Wang YX, Li Y, Jiang XY, Wang XF, Qiu MS, Lu PH, Xu XM (2008) Platelet-derived growth factor-AA mediates oligodendrocyte lineage differentiation through activation of extracellular signal-regulatedkinase signaling pathway. Neuroscience 151:138–147. CrossRef Medline
9. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649– 659. CrossRef Medline
10. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708–2714. CrossRef Medline
11. Kinjo S, Hirato J, Nakazato Y (2008) Low grade diffuse gliomas: shared cellular composition and morphometric differences. Neuropathology 28: 455–465. CrossRef Medline
12. Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L (2009) Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 28:2266–2275. CrossRef Medline
13. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, Foreman O, Bronson RT, Nishiyama A, Luo L, Zong H (2011) Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 146:209– 221. CrossRef Medline
14. Liu Y, Han SS, Wu Y, Tuohy TM, Xue H, Cai J, Back SA, Sherman LS, Fischer I, Rao MS (2004) CD44 expression identifies astrocyte-restricted precursor cells. Dev Biol 276:31– 46. CrossRef Medline
15. Louis DN, Ohgaki H, Wiestler OD, CaveneeWK (2007) WHOclassification of tumours of the central nervous system, fourth edition. Lyon, Franch: IARC.
16. Menn B, Garcia-Verdugo JM, Yaschine C, Gonzalez-Perez O, Rowitch D, Alvarez-Buylla A (2006) Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 26:7907–7918. CrossRef Medline
17. Mokhtari K, Paris S, Aguirre-Cruz L, Privat N, Crinière E, Marie Y, Hauw JJ, Kujas M, Rowitch D, Hoang-Xuan K, Delattre JY, Sanson M (2005) Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol 31:62– 69. CrossRef Medline
18. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002– 6007. CrossRef Medline
19. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer Rachamimov AO (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258– 2264. CrossRef Medline
20. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15 [suppl 2]:21–56. CrossRef Medline
21. Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC (2014) Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 26:288 –300. CrossRef Medline
22. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, McKnight TR, Goldman SA, WeissWA (2010) Non-stem cell origin for oligodendroglioma. Cancer Cell 18:669–682. CrossRef Medline
23. Sanai N, Chang S, Berger MS (2011) Low-grade gliomas in adults. J Neurosurg 115:948 –965. CrossRef Medline
24. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154. CrossRef Medline
25. Scherer SS, Braun PE, Grinspan J, Collarini E, Wang DY, Kamholz J (1994) Differential regulation of the 2',3'-cyclic nucleotide 3'-phosphodiesterase gene during oligodendrocyte development. Neuron 12:1363–1375. CrossRef Medline
26. Schnitzer J, Franke WW, Schachner M (1981) Immunocytochemical demonstration of vimentin in astrocytes and ependymal cells of developing and adult mouse nervous system. J Cell Biol, 90:435– 447. CrossRef Medline
27. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27–37. CrossRef Medline
28. Setoguchi T, Kondo T (2004) Nuclear export of OLIG2 in neural stem cells is essential for ciliary neurotrophic factor-induced astrocyte differentiation. J Cell Biol 166:963–968. CrossRef Medline
29. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA (2001) Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413:86 –91. CrossRef Medline
30. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.J Clin Oncol 26:1338 –1345. CrossRef Medline
31. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC (2002) Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 62:5551–5558. Medline
32. Uhrbom L, Kastemar M, Johansson FK, Westermark B, Holland EC (2005) Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res 65:2065–2069. CrossRef Medline
33. Wang J, Bushman J, Wang X, Mayer-Proschel M, Johnson M, Noble M (2013) Oligodendrocyte/type-2 astrocyte progenitor cells and glialrestricted precursor cells generate different tumor phenotypes in response to the identical oncogenes. J Neurosci 33:16805–16817. CrossRef Medline
34. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360:765– 773. CrossRef Medline
35. Yuan X, Chittajallu R, Belachew S, Anderson S, McBain CJ, Gallo V (2002) Expression of the green fluorescent protein in the oligodendrocyte lineage: a transgenic mouse for developmental and physiological studies. J Neurosci Res 70:529–545. CrossRef Medline
36. Zhou Q, Choi G, Anderson DJ (2001) The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron 31:791– 807. CrossRef Medline
37. Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC, Lev D (2011) Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene, 30:457– 470. CrossRef Medline